Posted by Michael Wonder on 18 Nov 2024
Alentis receives FDA fast track designation for ALE.P02 for the treatment of CLDN1 positive squamous solid tumours
18 November 2024 - ALE.P02 is a first in class antibody-drug conjugate targeting CLDN1.
Alentis Therapeutics announced today that the US FDA has granted fast track designation to ALE.P02 for the treatment of advanced or metastatic CLDN1 positive squamous cancers irrespective of the organ of origin.
